Peptide News Digest

Judge Won't Block Lilly's Zepbound Ads, GLP-1s on Breast Cancer Endocrine Therapy, Nerve Compression After Bariatric Surgery

A judge denies Novo's bid to halt Lilly's Zepbound ads, GLP-1s yield 4.5% loss on breast cancer endocrine therapy, and two peptide lab advances.

5 stories · Covering industry, research

Editor's Note

Monday's biggest item came from a New Jersey courtroom, where a federal judge declined Novo Nordisk's request to stop Eli Lilly's Zepbound and Mounjaro ads while their false-advertising case proceeds; he found Novo had not shown irreparable harm and did not rule on whether the ads are misleading. Two records studies showed that GLP-1 results depend on who is taking the drug. At Mount Sinai, breast cancer patients on hormone-blocking therapy lost an average of 4.5% of their weight in a year, well short of trial results, and a Washington University study linked GLP-1 use after bariatric surgery to more diagnoses of carpal and cubital tunnel syndrome, the nerve compression sometimes called slimmer's palsy. Outside GLP-1 drugs, Hong Kong dentists tested a peptide that helps damaged tooth pulp rebuild dentin in rats, and an Aarhus team worked out why the 1967 antibiotic lasso peptide triculamin needs an unusual tail to be made at all.

Industry

Federal Judge Denies Novo Nordisk's Bid to Block Lilly's Zepbound and Mounjaro Ads, Finding No Irreparable Harm

U.S. District Judge Zahid Quraishi in Trenton, New Jersey refused on October 26, 2026 to issue a preliminary injunction against Eli Lilly's ads for Zepbound and Mounjaro, which Novo Nordisk sued over in July for comparing higher doses of Lilly's drugs with lower doses of Wegovy and Ozempic, Reuters reported. After a two-day hearing in late August, the judge found Novo had not shown the ads hurt its sales, goodwill, or clinical reputation, noting its prescriptions stayed stable from April to July and that money damages could cover any harm. He did not decide whether the ads are false or misleading; Novo said the litigation continues, and Lilly, which denies wrongdoing, said it was pleased.

#eli-lilly #novo-nordisk #zepbound #wegovy #litigation
Research

Breast Cancer Patients on Endocrine Therapy Lost 4.5% of Body Weight in a Year on GLP-1 Drugs at Mount Sinai, Far Below Trial Results

Mount Sinai Hospital breast oncologists reported in Breast Cancer Research and Treatment on October 26, 2026 a retrospective study of 269 patients taking a GLP-1 drug for at least a year alongside adjuvant endocrine therapy for hormone receptor-positive breast cancer. Average weight loss at 12 months was 4.5% (3.9 kg), with 21.3% losing at least 10% and 10.4% at least 15%; semaglutide users lost 5.8% and tirzepatide users 4.7%, while dulaglutide users were unchanged. Patients whose tumors were PR-negative lost more than PR-positive patients (8.2% vs 4.2%), 70.6% had type 2 diabetes, and the single-center design means the comparison with trial results is indirect.

#breast-cancer #semaglutide #tirzepatide #real-world-evidence
Research

GLP-1 Use After Bariatric Surgery Linked to 63% Higher Rate of Carpal Tunnel and Double the Rate of Cubital Tunnel Diagnoses

Washington University School of Medicine researchers reported in HAND on October 26, 2026 a TriNetX study of 11,158 matched pairs of adults who had bariatric surgery between January 2015 and February 2026, with or without a GLP-1 drug. Over a median year of follow-up, GLP-1 users had more new carpal tunnel syndrome diagnoses (risk ratio 1.63) and cubital tunnel syndrome diagnoses (2.10) and more nerve-conduction testing (1.43), but carpal tunnel release surgery rates did not differ significantly. The GLP-1 group was younger and had a lower BMI at baseline, and the authors say more work is needed on mechanisms and monitoring.

#glp-1 #bariatric-surgery #side-effects #real-world-evidence
Research

University of Hong Kong Team's GSK-3β-Blocking Peptide L803-mts Rebuilds Dentin in Injured Rat Teeth at Density Similar to Standard MTA

Dental researchers at the University of Hong Kong reported in the International Endodontic Journal on October 26, 2026 that L803-mts, a peptide that inhibits the enzyme GSK-3β and so activates Wnt signaling, increased mineral formation and dentin-building markers in dental pulp stem cells under inflammatory conditions and shifted macrophages toward an anti-inflammatory state. In a rat pulp-injury model, new dentin made with L803-mts reached a mineral density similar to mineral trioxide aggregate, the standard capping material (1.17 vs 1.32 gHA/cm³), but with lower mineral volume (0.03 vs 0.06 mm³). The authors see it as a candidate for vital pulp therapy; the work has not been tested in people.

#preclinical #wnt #dental
Research

Aarhus Team Finds the 1967 Antibiotic Lasso Peptide Triculamin Needs an Unusual 'Follower' Tail to Be Made

Researchers at Aarhus University's Department of Biological and Chemical Engineering reported in The Journal of Antibiotics on October 26, 2026 that the follower peptide attached to triculamin's precursor, a feature unlike other lasso peptides, is essential for making the antibiotic. Structural predictions and targeted mutations suggest the follower binds the ring-closing enzyme and delivers the core peptide to its active site. The team made triculamin analogs by changing the core peptide, identified lysine-3 in the ring as the acetylation site, and found Burkholderia sp. FERM BP-3421 to be a better host for producing it.

#antimicrobial-peptides #lasso-peptides #peptide-discovery

Related Guides